Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NewcelX Ltd. (NCEL : NSDQ)

• Company Description    NewcelX is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. NewcelX, formerly known as NLS Pharmaceutics Ltd., is based in NESS ZIONA, Israel. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $3.16 Daily Weekly Monthly 20 Day Moving Average: 40,549 shares Shares Outstanding: 5.35 (millions) Market Capitalization: $16.89 (millions) Beta: 1.01 52 Week High: $30.80 52 Week Low: $1.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -35.64% -38.79% 12 Week 10.10% 1.79% Year To Date 66.32% 53.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL THE CIRCLE 6 - ZURICH,V8 8058 CHE ph: 41-44-512-2150 fax: 41-41-618-8009 None http://www.nlspharma.com

• General Corporate Information    Officers Ronen Twito - Executive Chairman and Chief Executive Officer Omri Hagai - Chief Financial Officer Michel Revel - Director Olivier Samuel - Director Eran Iohan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H5835A109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 5.35 Most Recent Split Date: 10.00 (0.10:1) Beta: 1.01 Market Capitalization: $16.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.99 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - - 12/31/25 - - 09/30/25 - - Current Ratio 03/31/26 - - 12/31/25 - 0.76 09/30/25 - - Quick Ratio 03/31/26 - - 12/31/25 - 0.76 09/30/25 - - Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 1.59 09/30/25 - - Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - -

Powered by Zacks Investment Research ©